Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

2010 ◽  
Author(s):  
Victor M. Rivera ◽  
Rana Anjum ◽  
Frank Wang ◽  
Sen Zhang ◽  
Jeffrey Keats ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Active Inhibitor ◽  
Anaplastic Lymphoma ◽  
Pharmacodynamic Analysis ◽  
Orally Active

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

2016 ◽  
Vol 59 (10) ◽  
pp. 4948-4964 ◽  
Author(s):  
Wei-Sheng Huang ◽  
Shuangying Liu ◽  
Dong Zou ◽  
Mathew Thomas ◽  
Yihan Wang ◽  
...  
Keyword(s):  
Phosphine Oxide ◽  
Anaplastic Lymphoma Kinase ◽  
Active Inhibitor ◽  
Anaplastic Lymphoma ◽  
Orally Active

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

2012 ◽  
Vol 20 (3) ◽  
pp. 1271-1280 ◽  
Author(s):  
Kazutomo Kinoshita ◽  
Kohsuke Asoh ◽  
Noriyuki Furuichi ◽  
Toshiya Ito ◽  
Hatsuo Kawada ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Design And Synthesis ◽  
Anaplastic Lymphoma ◽  
Orally Active

Anaplastic Lymphoma Kinase in Human Cancer

2012 ◽  
Vol 17 (2) ◽  
pp. 123-143 ◽  
Author(s):  
Christina Schonherr ◽  
Bengt Hallberg ◽  
Ruth Palmer
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Human Cancer ◽  
Anaplastic Lymphoma
Sign in / Sign up

Export Citation Format

Share Document